RBC Capital raised the firm’s price target on Danaher to $292 from $260 and keeps an Outperform rating on the shares. The company’s Q2 results were better than feared, and while destocking has been an overarching headwind for bioprocessing, customers are seen as working through their inventory and have signaled a bottom within 2023, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DHR: